Reviva Pharmaceuticals GAAP EPS of -$0.17 beats by $0.23
- Reviva Pharmaceuticals press release (RVPH): Q3 GAAP EPS of -$0.17 beats by $0.23.
- As of September 30, 2026, the company’s cash and cash equivalents totaled approximately $17.5 million compared to approximately $14.4 million as of December 31, 2025.
Recommended For You
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
Black Friday: Create a Free Seeking Alpha Account
See what's moving the market with unlimited news access, and get 20% off your first year of any Seeking Alpha service.
KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.